reflecting increased Pharma Thank gross cost you, savings by company Benefits second Jason, segment. initiatives chain from SG&A increased results. I'll margin with this our inflationary some driven Consolidated everyone. quarter and begin today Total X%, costs. the increase. good both morning, our increased consolidated revenue and X%, primarily offset of enterprise-wide supply XX%
the by quarter the was reflects year, $XXX segment line in decline in of were in second Operating this Medical Pharma of anticipated. growth last million segment which with offset earnings profit profit,
decreased and others primarily cash Moving million interest from interest increased line, below by equivalents. XX% driven and nearly to $XX the income
debt fixed a As largely rates. reminder, net our resulting interest in a rising benefit is rate, from
to effective year a our a positive program, billion net finished rate period. approximately we year prior in quarter $XXX second share year, the lower second average were new prior Our to $X than accelerated In than shares million repurchase percentage Diluted items in tax a year-to-date. discrete $XXX at X% points XX%, X.X resulting ago billion repurchases. of weighted due quarter, program completed million, the $X.XX total share primarily due deployed higher and initiated
shareholder growth the which $X fiscal reflects share XXXX, continue expect on continued billion per net billion was The share of quarter to maximizing X% to in focus to earnings $X.XX. result repurchases value. We in our $X.X for
period We adjusted the cash facility. no our turning million, generated ended flow billion quarter balance year-to-date credit cash $X.X with position cash bringing flow We to borrowings Now a on outstanding $XXX with adjusted free $XXX second of of the sheet. free to million.
XXXX expect pay of at $XXX hand. to down the million reminder, continue notes a with As on March maturity cash we to
I performance, with Now Slide will segment X. cover beginning Pharma our on
was brand driven partially This Branded offset and increased by supply million. program Pharma revenue and inflationary growth segment to a Pharmaceutical from X% chain to Products quarter Generics new Specialty higher net billion, XX% costs. existing by by contribution $XX Second performance, increased from sales driven and $XXX customers. Specialty profit
During To contributions we overall and a market. pharmaceutical others robust a demand, strength flu products saw from and saw more cold extent, noted. as customers the seasonality in year-over-year the quarter, we the new that net largest from cough, with our lesser customers, mentioned have their strong including previously we've reflecting also
and maximizing manage our controlling chain, Regarding our pleased only Generics solid we execution in with and delivery opioid-related program, customers. but we to our are transportation generally includes to by dynamics quarter, This Sourcing, Within also ERP Red with tailwinds year-over-year market our Oak this performance last headwind impacts consistent consistent expectations. we were costs of lower was inflationary effectively from through being and quarter, to the second costs. for inflationary technology Similar see. the from the areas the industry-wide complete not continue labor. continue in legal these offset supply service our enhancements costs, In strong
Okay.
Medical to X. Slide on Turning
to X% billion, decreased lower products revenue volumes. and PPE quarter including Second $X.X by distribution sales, and driven pricing
At-Home by Continued offset lower and strong finished an commentary, growth profit and our PPE improvement Solutions our segment margin. partially decline. volumes net offset in distribution inflationary to $XX was prior products with business Medical partially impact, primarily decreasing line this million. to due in in This XX%
mitigation driven impact we of quarter. pricing implementation This inflation our net from the efforts, the expectations, inflation over our including XX%. of product achieved of line mitigation by quarter from and improvement continued quarter, the additional the was in acceleration actions sequential the was During in with first the
we basis, Products sequential On we saw slight softness including overall discussed our a business. volumes With generally did second our earnings volume consistent two our the volumes last Health some a overall calls, products. on improvement In in sequential on see basis. have Distribution Cardinal brand PPE, in to and we respect quarter,
sheet normalized our margins the PPE significant Additionally, inventory in to quarter. made higher progress cost leading through we our selling in on balance
fiscal Now updated XXXX beginning for on Slide our X. outlook
Pharmaceutical $X.XX by $X.XX, million the improvement We to update raising other the at at the expect our segment by equivalents. a range $X.XX at primarily the end with in are which X% and interest interest the interest EPS outlooks improved $XXX of million the and now new midpoint. of We cash for growth increased guidance lower end represents This and $X.XX for on to $XXX reflects driven year-over-year higher to other. in income in range the
expectations the X remain Slide listed remaining unchanged. on items Our for
Turning in segment. Pharmaceutical to the Slide X
new new strong range a raising are revenue XX% of both outlook X.X% reflect of for to first our for a to our of to range X% growth, performance. primarily XX% We profit to growth segment and which half
be As third in to the the profit we quarters. balanced and we to fairly half between the growth anticipate look year-over-year pharma, fourth second
Turning to medical.
approximately $XXX expect we a and expect segment X% to X% in a from minimal XXXX our XX%. to fiscal With revenue ranging We impact. to actions, of continue impact flat decline profit net a of of year-over-year continue to respect to inflation a decline mitigation or million and
along while side, improvement in seen at still a levels, most general On freight. elevated stabilization areas we’ve with cost the international across
As costs in and a quarter of on delay. reminder, the chain are P&L these capitalized into approximate reflected product current our an in two supply elongated environment results inventory
profit. to no at And expected year the segment finally, inflation run continue to cadence we least expect Medical XX% exit a Importantly, of with of rate changes mitigation. the to
measures. continued in to and the be of primarily sequencing improve our our and extent, implementation sequentially to particularly improvement a cost toward reflects to inflation, the expect gradual and lesser around profit continue savings This fourth impact segment of quarter. volumes We net assumptions weighted the a overall
first segment. volume, lower profit of a medical, if and half, we’ve pharmaceutical in strength the the to more overall including segment rate the Pharma the enterprise, expect segment a year and we range factor Therefore, date. would end environment. the than in demand in we Health of in continued key a continues end towards the towards the utilization Cardinal albeit, upper demand In from at For continue, gradual of pharma, overall anticipate with our the in more improvement moderate more Medical the our the range be overall to expect we seen In second trends Brand. half
With that, it I’ll now to turn Jason. over
